In recent years, a large number of clinical evidence suggested that CCRT could improve the survival rate of patients with locally advanced NPC and the 5-year DMFS attained up to 74.7% – 85.8% [19–21], at the same time anti-EGFR Mab treatment also made clinical benefit in NPC patients [7, 22]. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.